Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2004-06-10
2009-10-13
Stucker, Jeffrey (Department: 1649)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C435S320100, C435S325000, C435S368000, C536S023100, C530S300000
Reexamination Certificate
active
07601518
ABSTRACT:
The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.
REFERENCES:
patent: 6361771 (2002-03-01), Tao et al.
patent: 2005/0158824 (2005-07-01), Pederson et al.
patent: 9306116 (1993-04-01), None
patent: 9708196 (1997-03-01), None
patent: 0001815 (2000-01-01), None
patent: 0004050 (2000-01-01), None
patent: 0018799 (2000-04-01), None
patent: WO 0052158 (2000-09-01), None
patent: WO 01/47946 (2001-05-01), None
patent: 02051433 (2002-07-01), None
patent: 02060929 (2002-08-01), None
patent: 02072826 (2002-09-01), None
patent: WO 02/078730 (2002-10-01), None
patent: WO 02/078730 (2002-10-01), None
patent: 2004/094592 (2004-11-01), None
patent: 2004/108760 (2004-12-01), None
patent: 2005/039643 (2005-05-01), None
Baudet et al., Development 127: 4335-4344, 2000.
Bonde et al., Neuroreport 11:4069-4073, 2000.
Wells, Biochemistry 29:8509-8517, 1990.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Bork, Genome Research 10:398-400, 2000.
Skolnick et al., Trends in Biotech. 18(1):34-39, 2000.
Doerks et al., Trends in Genetics 14:248-250, 1998.
Smith et al., Nature Biotechnology 14:1222-1223, 1997.
Brenner, Trends in Genetics 15:132-133, 1999.
Bork et al., Trends in Genetics 12:425-427, 1996.
Merlo et al., Cell Growth & Differentiation 1: 463-472, 1990.
Palmiter et al. PNAS 88: 478-484, 1991.
Hall et al. JBC 265: 19996-19999, 1990.
Lone Fjord-Larsen et. al., “Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construcct”, Experimental Neurology, pp. 1-12, Mar. 21, 2005.
Mart Saarma et. al., “GDNF—a stranger in the TGF-β superfamily?”,European Journal of Biochemistry, vol. 267, pp. 6968-6971, Feb. 2000.
Robert J. Baloh et al., “Functional mapping of Receptor Specificity Domains of Glial Cell Line-derived Neurotrophic Factor (GDNG) Family Ligands and Production of GFRα1 RET-specific Agonists”,The Journal of Biological Chemistry, vol. 275, No. 5, pp. 3412-3420, Feb. 4, 2000.
Aebischer, et al., “Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients”,Nature Medicine, vol. 2, No. 6, pp. 696-699, Jun. 1996.
Aebischer, et al., “Recombinant proteins for neurodegenerative diseases: the delivery issue”,Trends in Neurosciences, vol. 24, No. 9, pp. 533-540, Sep. 2001.
Bendtsen, et al., “Improved Prediction of Signal Peptides: SignalP 3.0”,J. Mol. Biol., vol. 340, pp. 783-795, 2004.
Hoane, et al., “Mammalian-Cell-Produced Neurturin (NTN) Is More Potent Than PurifiedEscherichia coli-Produced NTN”,Experimental Neurology, vol. 162, pp. 189-193, 2000.
Li, et al., “Expression, purification, and characterization of recombinant human neurturin secreted from the yeastPichia pastoris”, Protein Expression and Purification, vol. 30, pp. 11-17, 2003.
Milbrandt, et al., “Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin”,Neuron, vol. 20, pp. 245-253, Feb. 1998.
Nielsen, et al., “Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites”,Protein Engineering, vol. 10, No. 1, pp. 1-6, 1997.
Nielsen, et al., “Prediction of signal peptides and signal anchors by a hidden Markov model”, In. J. Glasgow et al., Eds.,Proc. Sixth Int. Conf. on Intelligent Systems for Molecular Biology, pp. 1-9, 1998.
Rosenblad, et al., “In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin”,Molecular and Cellular Neuroscience, vol. 15, pp. 199-214, 2000.
Tseng, et al., “Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy”,Neuroreport, vol. 9, pp. 1817-1822, Jun. 1, 1998.
Gronborg Mette
Kusk Philip
Tornoe Jens
Wahlberg Lars U.
Dutt Aditi
Elrifi Ivor
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
NsGene A/S
Snedden Sheridan K.
LandOfFree
Secretion of neublastin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Secretion of neublastin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Secretion of neublastin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120654